Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 25, showing 5 Applications out of 123 total, starting on record 36, ending on 40

# Protocol No Study Title Investigator(s) & Site(s)

36.

ECCT/22/10/05   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Videlis N Nduba
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
 
View

37.

ECCT/22/10/03   ISSC
    A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected childrenread more
Principal Investigator(s)
1. Eunice Akinyi Ouma
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital
 
View

38.

ECCT/22/10/02   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Janet N Oyieko
Site(s) in Kenya
1. Kombewa Clinical Research Centre (Kisumu county)
2. Victoria Biomedical Researchread more
View

39.

ECCT/22/09/01   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.read more
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Godfrey Allan Otieno
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2.read more
View

40.

ECCT/22/08/02   AIM-LVRNA009-II_III-01
    A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNAread more
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Otieno
3. Videlis Nduba
4. Bernhards Ogutu
5. Jacqueline Mirera
6. Jacqueline Mirera
read more
View